Trials / Completed
CompletedNCT00245973
Study Evaluating Bifeprunox in Bipolar Depression
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 380 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bifeprunox |
Timeline
- Start date
- 2005-06-01
- Completion
- 2007-10-01
- First posted
- 2005-10-28
- Last updated
- 2007-12-05
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00245973. Inclusion in this directory is not an endorsement.